GNFT Quote, Financials, Valuation and Earnings

Akari Therapeutics PLC has a net margin of -- compared to Genfit SA's net margin of --. Genfit SA's return on equity of -- beat Akari Therapeutics PLC's return on equity of --.

Genfit SA has a consensus price target of $8.70, signalling upside risk potential of 105.25%. On the other hand Akari Therapeutics PLC has an analysts' consensus of $7.00 which suggests that it could grow by 449.02%. Given that Akari Therapeutics PLC has higher upside potential than Genfit SA, analysts believe Akari Therapeutics PLC is more attractive than Genfit SA.

Genfit SA has a beta of 1.148, which suggesting that the stock is 14.837% more volatile than S&P 500. In comparison Akari Therapeutics PLC has a beta of 0.247, suggesting its less volatile than the S&P 500 by 75.292%.

Genfit SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Akari Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genfit SA pays -- of its earnings as a dividend. Akari Therapeutics PLC pays out -- of its earnings as a dividend.

Genfit SA quarterly revenues are --, which are smaller than Akari Therapeutics PLC quarterly revenues of --. Genfit SA's net income of -- is lower than Akari Therapeutics PLC's net income of -$3.7M. Notably, Genfit SA's price-to-earnings ratio is 32.57x while Akari Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genfit SA is 2.94x versus -- for Akari Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.

Cellectis SA has a net margin of -- compared to Genfit SA's net margin of -170.14%. Genfit SA's return on equity of -- beat Cellectis SA's return on equity of -49.15%.

Genfit SA has a consensus price target of $8.70, signalling upside risk potential of 105.25%. On the other hand Cellectis SA has an analysts' consensus of $5.75 which suggests that it could grow by 307.8%. Given that Cellectis SA has higher upside potential than Genfit SA, analysts believe Cellectis SA is more attractive than Genfit SA.

Genfit SA has a beta of 1.148, which suggesting that the stock is 14.837% more volatile than S&P 500. In comparison Cellectis SA has a beta of 2.924, suggesting its more volatile than the S&P 500 by 192.353%.

Genfit SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genfit SA pays -- of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend.

Genfit SA quarterly revenues are --, which are smaller than Cellectis SA quarterly revenues of $10.7M. Genfit SA's net income of -- is lower than Cellectis SA's net income of -$18.1M. Notably, Genfit SA's price-to-earnings ratio is 32.57x while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genfit SA is 2.94x versus 2.89x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.

DBV Technologies SA has a net margin of -- compared to Genfit SA's net margin of --. Genfit SA's return on equity of -- beat DBV Technologies SA's return on equity of --.

Genfit SA has a consensus price target of $8.70, signalling upside risk potential of 105.25%. On the other hand DBV Technologies SA has an analysts' consensus of $14.76 which suggests that it could grow by 63.98%. Given that Genfit SA has higher upside potential than DBV Technologies SA, analysts believe Genfit SA is more attractive than DBV Technologies SA.

Genfit SA has a beta of 1.148, which suggesting that the stock is 14.837% more volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.624, suggesting its less volatile than the S&P 500 by 162.448%.

Genfit SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genfit SA pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

Genfit SA quarterly revenues are --, which are smaller than DBV Technologies SA quarterly revenues of --. Genfit SA's net income of -- is lower than DBV Technologies SA's net income of -$27.1M. Notably, Genfit SA's price-to-earnings ratio is 32.57x while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genfit SA is 2.94x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

Edap TMS SA has a net margin of -- compared to Genfit SA's net margin of -52.18%. Genfit SA's return on equity of -- beat Edap TMS SA's return on equity of -49.1%.

Genfit SA has a consensus price target of $8.70, signalling upside risk potential of 105.25%. On the other hand Edap TMS SA has an analysts' consensus of $5.75 which suggests that it could grow by 234.3%. Given that Edap TMS SA has higher upside potential than Genfit SA, analysts believe Edap TMS SA is more attractive than Genfit SA.

Genfit SA has a beta of 1.148, which suggesting that the stock is 14.837% more volatile than S&P 500. In comparison Edap TMS SA has a beta of 0.015, suggesting its less volatile than the S&P 500 by 98.469%.

Genfit SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edap TMS SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genfit SA pays -- of its earnings as a dividend. Edap TMS SA pays out -- of its earnings as a dividend.

Genfit SA quarterly revenues are --, which are smaller than Edap TMS SA quarterly revenues of $14.3M. Genfit SA's net income of -- is lower than Edap TMS SA's net income of -$7.4M. Notably, Genfit SA's price-to-earnings ratio is 32.57x while Edap TMS SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genfit SA is 2.94x versus 0.95x for Edap TMS SA. Usually stocks with elevated PS ratios are considered overvalued.